Tscan therapeutics announces upcoming trial in progress poster presentation at the 2023 american society of clinical oncology annual meeting

Waltham, mass., june 01, 2023 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that the company will be presenting a trial in progress (tip) poster at the upcoming 2023 american society of clinical oncology (asco) annual meeting, being held from june 2-6, 2023, at mccormick place in chicago, illinois and online.
TCRX Ratings Summary
TCRX Quant Ranking